Facing anticipated reductions in funding and regulatory changes under the health care reform law, several of the nation's largest health insurers have indicated plans to scale back their Medicare Advantage programs.
Facing anticipated reductions in funding and regulatory changes under the health care reform law, several of the nation's largest health insurers have indicated plans to scale back their Medicare Advantage programs.
Beginning in 2014, insurers' Medicare Advantage plans will be held to a minimum medical-loss ratio of 85% under the Patient Protection and Affordable Care Act. The reform law also calls for a $156 billion reduction in Medicare Advantage payments by 2022.
Those cuts, coupled with the 2% overall reduction in Medicare spending under the Budget Control Act of 2011 and potential further cuts resulting from ongoing budget negotiations in Congress, prompted senior executives at several leading health insurers to outline planned withdrawals from certain Medicare Advantage markets and narrowed Medicare benefit plan offerings during recent calls with securities analysts.
Read the full story here: http://bit.ly/14VoXwo
Source: Business Insurance
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More